#161579

MB49-luc Cell Line

Please Enter Your Email ID
Email ID

Cat. #161579

MB49-luc Cell Line

Cat. #: 161579

Availability: 4-6 weeks

Organism: Mouse

Tissue: Bladder

Disease: Cancer

Model: Tumourigenic line

£1,110.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jeffrey Schlom, PhD

Institute: National Cancer Institute

Primary Citation: Vandeveer et al. Cancer Immunol Res. 2016 May, 4(5):452-62. PMID: 26921031

Tool Details
Target Details
Applications
Handling
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: MB49-luc Cell Line
  • Alternate name: MB49-luciferase, MB49-luc, MB-49-Luc, MB49luc, MB-49-luc, MB49-LUC, MB49 Luciferase (firefly) Cells
  • Cancer: Genitourinary cancer
  • Cancers detailed: Bladder
  • Research fields: Cancer
  • Parental cell: MB49 Cell Line
  • Organism: Mouse
  • Gender: Male
  • Tissue: Bladder
  • Disease: Cancer
  • Morphology: Epithelial cells
  • Growth properties: Adherent
  • Model: Tumourigenic line
  • Crispr: No
  • Conditional: No
  • Description: MB49-luc is an aggressive, bioluminescent orthotopic bladder cancer model stably expressing luciferase, derived from the well-established MB49 cell line. The bioluminescence can be detected by in vivo imaging and offers a readout for tumour take, growth and reduction. Similarly to its parental cell line MB49 (Cat. #: 153368), it forms tumours when injected subcutaneously or orthotopically into mouse bladders. Specifically, the orthotopic intravesical bladder tumour model based on MB49-luc offers a system to study immune-related factors involved in non-muscle invasive, non-metastatic bladder tumour growth, including anti-tumour effects of treatments such as immune checkpoint inhibitors. It also provides a bladder cancer model to study mechanisms of immunotherapy non-responders, to help identifying effective immune-based combination therapies and PD-L1 function within a tumour microenvironment devoid of T cells.
  • Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
  • Production details: Parental MB49 cells transfected with a pSELECT-zeo-LucSh plasmid using Lipofectamine (InvivoGen) for luciferase expression detected by in vivo imaging
  • Biosafety level: 1

Target Details

  • Target: PD-1, the programmed death-1 receptor
  • Target background: The programmed death-1 (PD-1) receptor is a checkpoint inhibitor, that interacts with distinct ligands, PD-L1 (B7-H1, CD274). PD-L1 is expressed on a wide variety of human and mouse tumour cells and some immune cell populations

Applications

  • Application: In vitro and in vivo model of bladder cancer; In vivo tumour imaging
  • Application notes: Identification host antitumor immune mechanisms and evaluation combinations of immune-based therapies for carcinoma in situ and non–muscle invasive, non-metastatic urothelial carcinoma

Handling

  • Growth medium: Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated foetal bovine serum supplemented with 1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM glutamine, and penicillin/streptomycin (100 U/mL).
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

Related Tools

  • Related tools: MB49 Cell Line

References

  • Domingos-Pereira et al. Int J Mol Sci. 2022. 24(1):123. PMID: 36613562.
  • Vandeveer et al. Cancer Immunol Res. 2016. 4(5):452-462. PMID: 26921031.